|
1) Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007; 12: 713-8
|
|
|
|
2) Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res. 2007; 13: 1961-70
|
|
|
|
|
|
3) Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis. 2007; 38: 258-68
|
|
|
|
|
|
4) Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25: 1539-44
|
|
|
|
|
|
5) Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004; 22: 2184-91
|
|
|
|
|
|
6) Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-50
|
|
|
|
|
|
7) Ramalingam SS, Dahiberg SE, Langer CJ, et al. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. Proc Am Soc Clin Oncol. 2007; 25: 393s
|
|
|
|
|
|
8) Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. Proc Am Soc Clin Oncol. 2007; 25: 388s
|
|
|
|
|
|
9) Ready N, Dudek AZ, Wang XF, et al. CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC). Proc Am Soc Clin Oncol. 2007; 25: 400s
|
|
|
|
|
|
10) Sandler A, Szwaric S, Dowlati A, et al. A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): A trial of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol. 2007; 25: 400s
|
|
|
|
|
|
11) Massarelli E, Miller VA, Leighl NB, et al. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA). Proc Am Soc Clin Oncol. 2007; 25: 416s
|
|
|
|
|
|
12) Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. Proc Am Soc Clin Oncol. 2007; 25: 276s
|
|
|
|
|
|
13) Hanna NH, Einhorn L, Sandler A, et al. Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 2005; 23: 622s
|
|
|
|
|